Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | PTGES | O14684 | 3/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.49 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895733 | 0.91 | LMNA (0.56) | LMNABCL2L1MCL1PTGESALDH1A1 | |
| SCHEMBL4898076 | 0.91 | LMNA (0.58) | LMNABCL2L1MCL1PTGESALOX5 | |
| SCHEMBL4904663 | 0.90 | LMNA (0.52) | LMNABCL2L1MCL1PTGESALOX5 | |
| SCHEMBL4907685 | 0.90 | LMNA (0.52) | LMNABCL2L1MCL1PTGESALOX5 | |
| SCHEMBL4903734 | 0.90 | LMNA (0.50) | LMNABCL2L1MCL1PTGESALOX5 | |
| SCHEMBL4900991 | 0.89 | LMNA (0.51) | LMNABCL2L1MCL1PTGESALOX5 | |
| SCHEMBL4902654 | 0.89 | LMNA (0.61) | LMNABCL2L1MCL1PTGESALOX5 | |
| SCHEMBL4899886 | 0.88 | LMNA (0.53) | LMNABCL2L1MCL1ALDH1A1HPGD | |
| SCHEMBL4903163 | 0.88 | LMNA (0.53) | LMNABCL2L1MCL1ALDH1A1HPGD | |
| SCHEMBL4895112 | 0.87 | LMNA (0.59) | LMNABCL2L1MCL1PTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765796-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | Pfizer Products Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006003495-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | claimed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | LMNA 317/4885BCL2L1 2170/4885MCL1 4160/4885 |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | LMNA 319/4885BCL2L1 2219/4885MCL1 4319/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | LMNA 319/4885BCL2L1 2219/4885MCL1 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.